The Advanced Therapies business unit of WuXi AppTec was formed in 2018 as a global Contract Development and Manufacturing Organization dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, protein, viral-based and other advanced therapies. By leveraging the integrated CDMO and testing services platforms, Wuxi Advanced Therapies provide solutions from gene of interest to global commercial launch, thereby reducing the complexities of multi-vendor production models. The services include process development, manufacturing capacity, analytical development, and raw materials management which are carried out within an extensive infrastructure of state-of-the-art GMP-compliant facilities.